Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.68%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.92%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.03%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.52%AUDUSD-1.45%AUDNZD-0.87%AUDCAD-0.87%EURAUD+0.87%AUDCHF-0.85%GBPAUD+0.80%GBPJPY-0.72%EURJPY-0.68%CHFJPY-0.67%NZDJPY-0.67%CADJPY-0.66%USDCHF+0.63%GBPUSD-0.63%USDCAD+0.59%EURUSD-0.59%NZDUSD-0.58%AUDSGD-0.50%USDZAR+0.45%AUDDKK-0.42%GBPTRY+0.41%USDTHB+0.36%AUDNOK-0.34%GBPHKD+0.32%EURZAR+0.30%NZDMXN+0.30%GBPMXN-0.28%USDMXN+0.28%GBPZAR+0.28%USDNOK+0.22%USDTRY+0.21%USDSEK+0.21%USDPLN+0.19%EURCNH-0.18%USDILS+0.16%USDDKK+0.15%EURHKD-0.15%CHFNOK+0.14%CHFSEK+0.12%USDCNH-0.11%NZDSGD+0.11%NOKJPY-0.10%USDJPY-0.09%GBPSGD-0.09%EURSGD-0.08%USDSGD+0.07%EURNOK+0.07%SGDJPY+0.06%GBPCAD-0.06%PLNJPY-0.06%EURSEK+0.06%GBPNZD-0.05%EURGBP+0.05%EURCHF+0.04%EURPLN+0.04%CADCHF+0.04%USDCOP-0.04%EURCZK+0.04%NZDCHF+0.03%EURNZD-0.02%CHFSGD-0.02%NZDCAD-0.01%EURCAD0.00%USDHKD0.00%GBPCHF0.00%EURDKK0.00%XNGUSD-0.62%XPTUSD-0.61%W1-0.42%C1-0.41%UKOIL+0.39%GAUUSD-0.32%XAUUSD-0.32%S1-0.23%XAGUSD-0.14%GAGUSD-0.14%COTTON+0.10%USOIL+0.07%BTCUSD-2.80%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+1.13%ZECUSDT-5.13%XMRUSDT-1.61%DOGEUSD+55.95%LINKUSD-2.46%XLMUSD-3.01%BCHUSDT-2.79%LTCUSD+47.50%UNIUSD-2.16%SUIUSD-1.92%TONUSD+59.18%HBARUSDT-4.33%TAOUSDT-1.85%AAVEUSD-2.60%ONDOUSDT-3.94%ICPUSDT-1.65%DOTUSDT-3.09%WLDUSDT-2.45%ARBUSDT-4.75%ATOMUSDT-1.71%INJUSDT-6.34%STXUSDT-0.96%PYTHUSDT+0.97%TIAUSDT-1.42%FETUSDT-3.75%JUPUSDT+2.15%SEIUSDT-2.00%GRTUSDT-2.58%OPUSDT-2.63%IOTAUSDT-1.19%POLUSDT-1.22%WIFUSDT-2.25%AXSUSDT-2.04%EOSUSDT-3.38%IMXUSDT-3.36%FARTCOINUSDT-5.08%GALAUSDT-1.65%DYDXUSDT-2.02%ORDIUSDT-1.49%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.79%KO-0.71%0700.HK-6.68%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.92%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.80%0857.HK-2.43%UNH-10.21%1288.HK-1.49%PM-0.85%0005.HK-2.03%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.52%AUDUSD-1.45%AUDNZD-0.87%AUDCAD-0.87%EURAUD+0.87%AUDCHF-0.85%GBPAUD+0.80%GBPJPY-0.72%EURJPY-0.68%CHFJPY-0.67%NZDJPY-0.67%CADJPY-0.66%USDCHF+0.63%GBPUSD-0.63%USDCAD+0.59%EURUSD-0.59%NZDUSD-0.58%AUDSGD-0.50%USDZAR+0.45%AUDDKK-0.42%GBPTRY+0.41%USDTHB+0.36%AUDNOK-0.34%GBPHKD+0.32%EURZAR+0.30%NZDMXN+0.30%GBPMXN-0.28%USDMXN+0.28%GBPZAR+0.28%USDNOK+0.22%USDTRY+0.21%USDSEK+0.21%USDPLN+0.19%EURCNH-0.18%USDILS+0.16%USDDKK+0.15%EURHKD-0.15%CHFNOK+0.14%CHFSEK+0.12%USDCNH-0.11%NZDSGD+0.11%NOKJPY-0.10%USDJPY-0.09%GBPSGD-0.09%EURSGD-0.08%USDSGD+0.07%EURNOK+0.07%SGDJPY+0.06%GBPCAD-0.06%PLNJPY-0.06%EURSEK+0.06%GBPNZD-0.05%EURGBP+0.05%EURCHF+0.04%EURPLN+0.04%CADCHF+0.04%USDCOP-0.04%EURCZK+0.04%NZDCHF+0.03%EURNZD-0.02%CHFSGD-0.02%NZDCAD-0.01%EURCAD0.00%USDHKD0.00%GBPCHF0.00%EURDKK0.00%XNGUSD-0.62%XPTUSD-0.61%W1-0.42%C1-0.41%UKOIL+0.39%GAUUSD-0.32%XAUUSD-0.32%S1-0.23%XAGUSD-0.14%GAGUSD-0.14%COTTON+0.10%USOIL+0.07%BTCUSD-2.80%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+1.13%ZECUSDT-5.13%XMRUSDT-1.61%DOGEUSD+55.95%LINKUSD-2.46%XLMUSD-3.01%BCHUSDT-2.79%LTCUSD+47.50%UNIUSD-2.16%SUIUSD-1.92%TONUSD+59.18%HBARUSDT-4.33%TAOUSDT-1.85%AAVEUSD-2.60%ONDOUSDT-3.94%ICPUSDT-1.65%DOTUSDT-3.09%WLDUSDT-2.45%ARBUSDT-4.75%ATOMUSDT-1.71%INJUSDT-6.34%STXUSDT-0.96%PYTHUSDT+0.97%TIAUSDT-1.42%FETUSDT-3.75%JUPUSDT+2.15%SEIUSDT-2.00%GRTUSDT-2.58%OPUSDT-2.63%IOTAUSDT-1.19%POLUSDT-1.22%WIFUSDT-2.25%AXSUSDT-2.04%EOSUSDT-3.38%IMXUSDT-3.36%FARTCOINUSDT-5.08%GALAUSDT-1.65%DYDXUSDT-2.02%ORDIUSDT-1.49%NOTUSDT+0.86%RONINUSDT-2.92%

Health Canada clears two Moderna mRNA shots

NEWS

November 5, 2026 at 23:01 UTC

4 min read
Unbranded vaccine vial in a bright clinic, illustrating Health Canada approval of new mRNA shots MRNA

Key Points

  • 01Health Canada authorized Moderna (MRNA)’s mFLUSIVA and mCOFLU vaccines for adults 50 and older
  • 02Canada becomes first country to clear both Moderna (MRNA)’s mRNA flu and combo flu-COVID shots
  • 03mFLUSIVA showed 26.6% relative efficacy vs a standard-dose flu vaccine in adults 50+
  • 04mCOFLU met all primary endpoints, with higher immune responses for three flu strains and SARS-CoV-2

Health Canada authorizes two Moderna mRNA vaccines

Health Canada has authorized Moderna’s mFLUSIVA influenza mRNA vaccine and its mCOFLU combined influenza and COVID-19 mRNA vaccine for adults 50 years of age and older. With these decisions, Canada becomes the first country to authorize both Moderna’s seasonal mRNA influenza vaccine and its combination influenza and COVID-19 vaccine. mFLUSIVA is described as Canada’s first mRNA-based seasonal influenza vaccine, while mCOFLU is the country’s first combination influenza and COVID-19 vaccine.

Both products are authorized for active immunization in adults 50 and older. mFLUSIVA is indicated for the prevention of influenza disease caused by influenza virus subtypes A and B represented in the vaccine. mCOFLU is indicated for the prevention of influenza caused by influenza A and B types represented in the vaccine and for the prevention of COVID-19 caused by SARS-CoV-2.

Clinical evidence for mFLUSIVA

The authorization of mFLUSIVA is supported by the pivotal Phase 3 mRNA-1010-P304 trial, a randomized, active-controlled study involving approximately 40,800 adults 50 years of age and older across 11 countries. In this study, mFLUSIVA met all pre-specified statistical success criteria, including the highest level of pre-specified superiority, with a relative vaccine efficacy of 26.6% in adults 50 and older versus a standard-dose inactivated influenza vaccine. Among adults 65 and older, relative vaccine efficacy was 27.4% versus the same comparator, against RT-PCR-confirmed, protocol-defined influenza-like illness caused by influenza A or B.

Additional support for mFLUSIVA comes from the Phase 3 mRNA-1010-P303 Part C study, which showed superior antibody responses compared with a high-dose inactivated influenza vaccine in adults 65 years of age and older. Across both key studies, the most commonly reported adverse reactions included injection-site pain, fatigue, headache, muscle pain, joint pain, chills and axillary (underarm) swelling or tenderness. Most solicited reactions were mild to moderate and resolved within one to two days.

Clinical evidence for mCOFLU

mCOFLU’s authorization is based on a pivotal Phase 3 randomized, observer-blind, active-controlled study evaluating safety, reactogenicity and immunogenicity in two cohorts of approximately 4,000 adults each. Adults 65 and older received either mCOFLU or co-administered Fluzone HD, a high-dose influenza vaccine, and Spikevax, Moderna’s licensed COVID-19 vaccine. Adults 50 to 64 years of age received either mCOFLU or co-administered Fluarix, a standard-dose influenza vaccine, and Spikevax.

The trial met all primary endpoints, demonstrating non-inferiority of immune responses versus the comparator regimen. After a single dose, mCOFLU elicited statistically significantly higher immune responses against three influenza strains—A/H1N1, A/H3N2 and B/Victoria—and against SARS-CoV-2 in both age cohorts. A higher immune response was not observed for the B/Yamagata strain in adults 65 and older, a strain that is no longer recommended for inclusion in seasonal influenza vaccines.

Safety profile and next steps in Canada

mCOFLU demonstrated an acceptable safety and tolerability profile in the pivotal study. The most commonly reported adverse reactions included injection-site pain, fatigue, muscle pain, headache, joint pain, chills and axillary swelling or tenderness, and most were mild to moderate and short in duration. No serious adverse events were assessed as related to mCOFLU in the pivotal trial.

Moderna plans to engage with Canadian health authorities and immunization partners as it advances plans for the future availability of mFLUSIVA and mCOFLU in Canada. Both vaccines remain under regulatory review in additional markets, following earlier approvals of mFLUSIVA in the United States and the combination vaccine in Europe.

Key Takeaways

  • 01Health Canada’s decision positions Canada as an early adopter of Moderna (MRNA)’s mRNA-based respiratory vaccines, including the country’s first mRNA seasonal flu shot and first flu-COVID combination.
  • 02Large Phase 3 programs underpin both authorizations, with mFLUSIVA showing moderate relative efficacy versus a standard-dose flu shot and strong antibody data in older adults.
  • 03mCOFLU’s non-inferior and, for several strains, higher immune responses compared with separate licensed vaccines, alongside a favorable safety profile, support its use as a consolidated respiratory immunization option for adults 50+.

Health Canada clears two Moderna mRNA shots | Trading Dashboard